Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
ConclusionIn real-world patients with mRCC, immunotherapy is associated with significant survival benefit. The present retrospective analysis shows the real-world benefit of second-line immunotherapy in patients previously treated with tyrosine –kinase inhibitors.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer & Oncology | Carcinoma | Databases & Libraries | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma